Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab
Sugemalimab added to standard CAPOX chemotherapy significantly improves overall survival and progression‑free survival in treatment‑naïve patients with unresectable locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with PD‑L1 CPS ≥ 5.
Bizonyítékszint: Irányelv / elfogadott gyakorlat. Magas szintű klinikai elfogadottság.
Kapcsolódó jelek
- Precision medicine in gastric cancer
- Gastric cancer
- DESTINY‑Gastric05 Phase 3 Trial of ENHERTU Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer
- Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies
- Nivolumab/Chemo Yields Long-Term Survival in Advanced Gastric Cancers